Eradivir Investment Fund — Ollin Ventures Co-Investments

Chapter One

Investment Overview

Executive Summary

Eradivir is a privately held, clinical-stage biotechnology company based in West Lafayette, Indiana, developing antibody-recruiting small molecules designed to direct the body's existing immune system toward viruses and diseased cells. The company was founded in 2020 by Dr. Philip S. Low and Martin Low around small-molecule targeting technology originating in Dr. Low's laboratory at Purdue University.

Eradivir's proprietary BAiT™ (Bispecific Antigenic immuno-Therapy) platform combines a disease-specific targeting ligand with immune-recruiting components designed to attract naturally circulating antibodies to a selected target. By changing the targeting ligand, Eradivir intends to apply the platform across multiple diseases while retaining a common underlying therapeutic architecture.

The company's lead program, EV25, is being developed for the treatment of influenza. EV25 has completed a randomized, double-blind, placebo-controlled Phase I/IIa clinical study that evaluated safety, tolerability, pharmacokinetics and efficacy in healthy volunteers and influenza-challenge participants. The final clinical study report documented dose-related reductions in viral load and statistically significant improvements in several symptom-related measures at the 300 mg dose. Eradivir is now advancing EV25 through additional Phase 2 development.

Eradivir's second major program, EV148, is being developed for respiratory syncytial virus (RSV). EV148 has demonstrated preclinical antiviral activity and is being advanced toward first-in-human development. The company is also evaluating the broader applicability of the BAiT platform across additional viral and non-viral diseases.

Ollin Ventures is preparing the Eradivir Investment Fund to participate in Eradivir's proposed Series C financing. Eradivir is currently targeting a $65 million Series C raise, with the Ollin-managed vehicle targeting up to $20 million of that financing. Valuation, security, price per share and final SPV economics have not yet been determined and must remain marked TBD until finalized.

Why This Opportunity Exists

MARKET NEED

Large Unmet Medical Need

Influenza and RSV continue to cause substantial global disease burden despite widespread vaccination and existing supportive or antiviral treatments. Current influenza therapies are generally most useful when administered early in the course of disease, leaving a meaningful treatment gap for patients who present later. RSV similarly lacks a broadly effective therapeutic option for many infected patients.

Eradivir company materials and public website.

PLATFORM

Differentiated Immune-Recruiting Platform

Eradivir's BAiT platform is designed to combine the specificity and manufacturability of small molecules with targeted recruitment of the body's existing immune system. The platform uses disease-specific targeting ligands linked to immune-recruiting haptens, creating a modular architecture that may be adaptable across multiple diseases.

Eradivir BAiT platform materials.

CLINICAL VALIDATION

Human Proof of Concept

EV25 has completed a Phase I/IIa randomized, double-blind, placebo-controlled clinical study. The study demonstrated an acceptable safety and tolerability profile and showed dose-related reductions in viral load, with statistically significant improvements in several influenza symptom measures at the 300 mg dose. These results provide human clinical validation of Eradivir's lead program and support continued development.

EV-FLU-CL-01 Final Clinical Study Report, September 30, 2025.

PIPELINE

Platform Expansion Beyond Influenza

Eradivir is advancing EV148 for RSV while evaluating additional applications of the BAiT platform. Preclinical work on EV148 has shown antiviral activity, and the company is preparing the program for clinical development. The broader platform creates the potential for Eradivir to develop multiple therapeutics from a shared scientific approach rather than relying on a single asset.

Eradivir company materials and 2026 shareholder updates.

Investment Snapshot

Eradivir has moved its lead BAiT program from discovery into human clinical testing while simultaneously advancing a second respiratory-virus program. The current financing is intended to support the next stage of development across EV25 and EV148 and position the company for major clinical and strategic milestones. For Ollin investors, the current opportunity provides exposure to Eradivir through a dedicated single-company investment vehicle. The Series C transaction is still being structured. Until final documentation is available, valuation, security, price per share, closing schedule and SPV economics must remain explicitly marked TBD.

Active

Company: Eradivir, Inc.
Sector: Biotechnology
Platform: BAiT™ — Bispecific Antigenic immuno-Therapy
Lead Program: EV25
Current Stage: Phase 2 clinical development
Headquarters: West Lafayette, Indiana
Financing Round: Series C
Company Raise: $65 million proposed
Ollin SPV Target: Up to $20 million
Security: TBD
Valuation: TBD
Use of Capital: Clinical development, manufacturing and continued advancement of Eradivir's pipeline; detailed Series C use of proceeds to be updated when finalized.

Chapter Two

Investment Highlights

PLATFORM

BAiT™ Platform Technology

Eradivir's proprietary Bispecific Antigenic Immuno-therapy (BAiT™) platform combines disease-specific targeting ligands with antibody-recruiting haptens to direct naturally circulating antibodies toward viruses and infected cells. The platform is designed to combine the simplicity, stability, and manufacturing advantages of small molecules with immune-mediated mechanisms more commonly associated with biologic therapies. Beyond influenza and RSV, the platform has potential applications across additional infectious diseases.

—Proprietary BAiT™ platform
—Multiple therapeutic applications
—Patent estate extending beyond 2044

CLINICAL

Clinical Proof of Concept

EV25 has demonstrated encouraging clinical performance in a randomized Phase 2a human influenza challenge study. Reported results include reductions in viral burden, improvements across multiple clinical symptom measurements, favorable safety observations, and immune response findings supporting continued development into larger efficacy studies.

—Phase 2a completed
—Human efficacy demonstrated
—Single-dose therapy

PIPELINE

Dual Clinical Pipeline

Eradivir is advancing two lead therapeutic programs built on the same BAiT™ platform. EV25 targets influenza and is currently progressing through Phase 2 development, while EV148 targets RSV and is preparing for early clinical studies. The shared platform provides opportunities to expand into additional disease areas over time.

—EV25 — Influenza
—EV148 — RSV
—Platform expansion potential

MARKET

Large Commercial Opportunity

Influenza and RSV continue to represent significant unmet medical needs worldwide despite vaccines and currently approved antivirals. Existing therapies often have limited treatment windows or reduced effectiveness in later-stage disease, creating meaningful commercial opportunities for differentiated therapeutic approaches.

—Multi-billion dollar market opportunity
—Significant unmet need
—Large global patient populations

CATALYSTS

Multiple Near-Term Milestones

The current financing is intended to support several value-inflecting milestones, including continued Phase 2 development of EV25, advancement of EV148 toward human studies, manufacturing activities, regulatory interactions, and additional clinical readouts expected over the next several years.

—Multiple clinical milestones
—Regulatory progress
—Manufacturing advancement

VALUE CREATION

Clear Development Strategy

Management's strategy is focused on systematically reducing clinical, manufacturing, and regulatory risk while advancing both lead programs toward commercialization. Successful execution may create opportunities for strategic partnerships, acquisition, or future public market financing following major clinical milestones.

—Clinical de-risking
—Platform expansion
—Multiple strategic exit pathways

Chapter Three

Sponsor Overview

Ollin Ventures has supported Eradivir through multiple financing rounds and is sponsoring the Eradivir Investment Fund to participate in the proposed Series C financing.

Existing Investment Position

Across multiple prior investment vehicles, Ollin-managed entities have invested approximately $12 million into Eradivir and currently own approximately 8.67% of the company on a fully diluted basis, subject to future financing dilution.

This long-term investment history reflects continued conviction in the company's technology, management team, and development strategy.

Capital Invested: Approximately $12M
Current Ownership: Approximately 8.67%
Investment History: Multiple Prior Financing Rounds
Current Status: Existing Shareholder

Investment Structure

The Eradivir Investment Fund is a special purpose investment vehicle (SPV) sponsored and managed by Ollin Ventures. Investors subscribe to the SPV, which is intended to participate directly in Eradivir's proposed Series C financing.

Alignment

Existing Shareholder

Ollin and its investors have maintained an ownership position through multiple financing rounds and intend to continue supporting the company's long-term development.

Long-Term Relationship

Ollin has developed an ongoing working relationship with Eradivir's management through years of diligence and investment participation.

Aligned Interests

Ollin's investment team invests alongside investors through the same SPV structure, aligning incentives throughout the investment lifecycle.

Investment History

Prior Investment
Follow-on Investments
Current Ownership Position
Proposed Series C Participation

Chapter Four

Transaction Summary

Eradivir is preparing a proposed Series C financing intended to support continued clinical development of EV25, advancement of EV148, manufacturing activities, and continued expansion of the BAiT™ platform. Ollin Ventures is sponsoring the Eradivir Investment Fund to participate in the financing. Certain financing terms remain under negotiation and have not yet been finalized.

Transaction Snapshot

Company: Eradivir
Financing Round: Series C
Company Raise: $65 million (proposed)
Ollin Allocation: Up to $20 million
Security: TBD
Pre-Money Valuation: TBD
Price Per Share: TBD
Lead Investor: TBD
Expected Closing: TBD
Status: Preliminary
Last Updated: TBD

SPV Economics

Vehicle: Eradivir Investment Fund
Manager: Ollin Ventures
Management Fee: 2% — collected at closing
Carried Interest: 20%
Investor Profit Participation: 80%
Minimum Investment: TBD
Additional SPV Expenses: TBD
Organizational Documents: TBD

Use of Proceeds

Clinical Development

Continue advancement of EV25 and EV148 through planned clinical milestones.

Manufacturing

Support formulation, CMC activities, manufacturing scale-up, and production readiness.

Regulatory

Support regulatory interactions, submissions, and future clinical planning.

Platform Expansion

Advance additional applications of the BAiT™ platform and supporting research.

Key Transaction Notes

Financing terms remain under negotiation.

Valuation has not yet been established.

Final allocation remains subject to company approval.

Information may be updated as diligence progresses.

Expected Milestones

Current Financing
Series C Close
Clinical Advancement
Regulatory Milestones
Future Value Inflection Points

Chapter Five

Development Timeline

Company Founded
Placeholder — content pending.
Technology Developed
Placeholder — content pending.
Clinical Progress
Placeholder — content pending.
Current Financing
Placeholder — content pending.
Future Milestones
Placeholder — content pending.

Chapter Six

Latest Updates

No updates have been published for this opportunity yet. Updates appear here as the transaction progresses.

Chapter Seven

Next Steps

Placeholder — next steps pending. Materials are shared by invitation only.

Request a meeting Request access

← All co-investments